Low-dose carboplatin modifies the tumor microenvironment to augment CAR T cell efficacy in human prostate cancer models.
Porter LH, Zhu JJ, Lister NL, Harrison SG, Keerthikumar S, Goode DL, Urban RQ, Byrne DJ, Azad A, Vela I, Hofman MS, Neeson PJ, Darcy PK, Trapani JA, Taylor RA, Risbridger GP.
Porter LH, et al. Among authors: taylor ra.
Nat Commun. 2023 Sep 2;14(1):5346. doi: 10.1038/s41467-023-40852-3.
Nat Commun. 2023.
PMID: 37660083
Free PMC article.